Novartis Nears Acquisition of Cytokinetics Following Biotech's Heart Disease Breakthrough
TL;DR Summary
Novartis is reportedly in talks to acquire Cytokinetics, with the potential deal expected to be finalized by the end of the week, following Cytokinetics' release of positive Phase III data for its heart disease program, aficamten, which has sparked M&A speculation and caused Cytokinetics' stock to surge nearly 15%.
- Updated: Novartis close to acquiring Cytokinetics after biotech's PhIII heart disease win — WSJ Endpoints News
- Novartis in Advanced Talks to Buy Cytokinetics - WSJ The Wall Street Journal
- Novartis in advanced talks to buy Cytokinetics- source Reuters
- Biotech Claws Back 105% Over A Week. Now It Could Score A Buyout. Investor's Business Daily
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
52%
103 → 49 words
Want the full story? Read the original article
Read on Endpoints News